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Objective: Cannabis is an acknowledged risk factor for some mental disorders, but for others 
the evidence is inconclusive. Prescribed medicinal drugs can be used as proxies for mental 
disorders. In this study, we investigate how use of cannabis is prospectively related to 
prescription of antipsychotics, mood stabilizers, antidepressants and anxiolytics.  
Methods: Data on cannabis exposure and relevant confounders were obtained from 2,602 
individuals in the longitudinal Young in Norway Study, providing survey data from four data 
collection waves between 1992 and 2006. Data were coupled with information about 
prescriptions for psychotropic drugs from the Norwegian Prescription Database between 2007 
and 2015.  
Results: Past year cannabis use increased the risk of prescription of antipsychotics (OR = 
5.56, 95 % CI 1.64 – 18.87), mood-stabilizers (OR = 5.36, 95 % CI 1.99 – 14.44) and 
antidepressants (OR = 2.10, 95 % CI 1.36 – 3.25), after accounting for socio-demographic 
variables, conduct problems, additional drug use, mental distress and prescriptions the year 
before cannabis use was measured. 
Conclusions: In this study of young adults from the general population, past year cannabis use 
was associated with later prescriptions of antipsychotics, mood-stabilizers and 
antidepressants.  
 







1 Cannabis use is associated with a five-fold increased risk for prescription of 
mood stabilizers and antipsychotics 
2 Cannabis use is associated with a smaller but significant increase in risk for 
prescription of antidepressants 
 
Limitations 
1 Using prescriptions as proxy measures for mental disorders may be imprecise 
2 A dose-response relationship could not be investigated due to too low statistical 
power  
 
Data availability statement 




Parallel with the past decade changes in cannabis regulation, rates of use, heavy use and 
addiction have increased (1, 2) and the products have become more potent (3, 4). Evidence 
suggests that cannabis use may increase the risk of mental disorders, with stronger 
associations for some disorders than for others.  
Numerous studies have described that cannabis use is associated with an increased risk 
of schizophrenia in a dose-related manner with relatively strong effect sizes (5): While the 
risk is approximately doubled for any use compared to no use, it increases six-fold when high 
consumers are compared to non-users (6, 7). The relationship remains strong after adjustment 
for relevant confounders, and also after accounting for genetic vulnerability (8, 9). Cannabis 
use is also associated with lower age of onset of schizophrenia (10, 11). Moreover, persons 
with first episode psychosis who use cannabis show worse functional and symptomatic long 
term outcomes, and these effects seem to be reversed when the consumption is discontinued 
(12). In spite of the strong empirical support for a causal association, a steep increase in 
cannabis consumption over decades unaccompanied by increased incidence of schizophrenia, 
has been used as an argument against a causal association (13). However, recent evidence 
suggests that areas with high potency cannabis in fact have higher incidence of schizophrenia 
(14), and the incidence of schizophrenia has increased in some countries (15). 
Bipolar disorder, a disease with some symptom and aetiological overlap with 
schizophrenia (16, 17), starts at a younger age for cannabis users compared to non-users (18, 
19). In clinical samples, cannabis use is associated with increased symptoms (20, 21), rapid 
cycling (22), lower remission rates (23, 24) and a three-fold increased risk for new onset of 
manic symptoms (25). While some studies have found that cannabis use increases the risk of 
first onset of manic symptoms (26) and bipolar disorder (27) by a factor of more than four, 
others have found the association to be non-significant after adjustment for confounders (28). 
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There is a growing conception that cannabis use can act as a risk factor for the onset of 
bipolar disorder (29) though the causal direction is debated (30).  
The evidence for depression and anxiety as consequences of cannabis exposure is 
mixed, with substantially lower effect sizes than for schizophrenia, and with the lower range 
of the confidence interval often close to the null-effect line (31, 32). A meta-analysis 
calculated the risk of depression to be increased by 1.62 (95% CI 1.21 – 2.16) for heavy 
cannabis use and 1.17 (1.05 – 1.30) for any use compared to no use (33). Another meta-
analysis including only studies of young adults also found cannabis users to have increased 
risk for depression relative to non-users (34). The association has remained after adjustment 
for genetic and environmental factors (35). For anxiety, one meta-analysis found an increased 
risk of 1.28 (95 % CI 1.06 – 1.54) following cannabis-exposure (36), while another found the 
association to be non-significant (34). However, several large individual studies have found 
that cannabis use is unrelated to both major depression and anxiety (28, 37-40).  
It seems reasonable to consider cannabis as a risk factor for schizophrenia, and 
perhaps also for bipolar disorder. The prospective relationship to depression is weaker and 
less consistent, and the association to anxiety is unclear and by some even rejected. However, 
comparison across studies is difficult due to differences in design, setting, definition of 
exposure and outcome, and inclusion of covariates. Longitudinal, population-based studies 
comparing all these outcomes would add valuable information.  
Due to low incidence rates of the outcomes, large studies, e.g. registry based are 
warranted. Some of those who have a mental disorder will receive pharmacological treatment 
for their conditions. Filling a prescription for a mental disorder may thus be used as an 
indirect measure of the disorders and have been used as such in previous studies (41, 42).  
Aims of the study: In this study, we investigate the association between cannabis 
exposure and later prescription of anti-psychotics, mood stabilizers, antidepressants and 
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anxiolytics. We include baseline measurement of a multitude of possible confounders, such as 
several variables of socio-demographic background, conduct problems, mental distress and 
use of other drugs of abuse. To decrease the possibility of reversed causality, we excluded 





Procedure and Participants 
The study was based on data from the Young in Norway study, described in more detail 
elsewhere (43). In short, the initial sample at T1 was composed of students in grades 7 through 
12 drawn from 67 junior and senior high schools in Norway (age span 12 to 20 years). The 
high initial response rate at T1 of 97 % was achieved by using substantial resources to follow 
up participating schools (44). The only exclusion criterion was severe lack of reading 
capability. Students were followed up in 1994 (T2), 1999 (T3) and 2006 (T4).The cumulative 
response rate across all four waves was 69%. At the last data collection, respondents were 
asked for their consent to link the data to several registers, to which 2,602 respondents (90%) 
agreed. The overall participation rate of the final sample was thus 60%. Of the final sample of 
2,602 respondents, 1,145 were male (44%) and 1,457 female (56%). The mean age of the 
participants across the four data collection waves were T1: 15.1 (SD = 2.0 years), T2: 16.5, T3: 
23.0 and T4: 28.5 years.  
Information about prescriptions for mental disorders was drawn from the Norwegian 
Prescription Database (NorPD). This registry is administered by the Norwegian Institute of 
Public Health and contains information on all prescriptions dispatched to pharmacies outside 
of institutions, prescribed to individuals, from 2004. The database includes information about 
date of prescription filling, anatomical-therapeutic-chemical (ATC) code of the drug, and 
number of daily defined doses. The outcomes in the current study included data from the 
NorPD from January 1st 2007 to December 31st 2015; 1 to 9 years after T4.  
 
Measures 
Prescription of psychotropic drugs. Subjects were categorized according to ATC-codes in 
mutually exclusive groups as receiving either anti-psychotics, mood-stabilizers, 
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antidepressants or anxiolytics during the nine-year period from 2007 to 2015. A fifth group 
was created to capture prescriptions that due to dose and type of medicine were evaluated to 
be psychotropic drugs for a non-psychiatric disorder (for instance nausea or epilepsy). The 
decision rules were hierarchical in the following order: 1) mood-stabilizers, 2) anti-
psychotics, 3) antidepressants, 4) anxiolytics and 5) psychotropic drugs on other indications. 
The hierarchy of categories was relevant for assigning category when a person had received 
medications from more than one category (e.g. if a person was prescribed both antidepressants 
and mood-stabilizers, the person was categorized as receiving mood-stabilizers). Some 
exceptions from the general rules were made to account for only low-dose prescriptions and 
cases of only one prescription. A detailed description of these categorizing principles is 
provided in the supplement. 
Cannabis use. Based on self-reported use of cannabis at T4, we divided the material 
into three categories: those who had never used cannabis; those who had used cannabis at 
least once in their lifetime, but not in the last 12 months; and those who had used cannabis at 
least once during the last 12 months. 
Socio-demographics. Age, gender and country of birth (Norway or abroad) were 
assessed at T1. The same was parental education, which was classified into five levels from up 
to 9 years of basic education (1) to more than three years of university education (5) for the 
parent with highest education. We also asked whether the respondent was living with both 
biological parents or not at T1.  
Conduct problems and drug use. We used a 15-item measure of conduct problems at 
T1, which approximates diagnostic criteria for conduct disorder in the DSM-III-R (45). 
Response options ranged from 1 (never) to 6 (more than 50 times). Mean scores across all 
items were computed (Cronbach’s α = 0.75). We assessed the number of alcohol intoxication 
episodes at T1 by asking how often respondents had drunken so much that they felt clearly 
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intoxicated during the previous 12 months. Response options ranged from 1 (never) to 6 
(more than 50 times). Moreover, we asked at T1 about daily smoking (no/yes) during the past 
12 months. We also assessed use of other illicit drugs than cannabis at T1 by asking whether 
the respondent had used “other narcotics than cannabis, such as cocaine, LSD, amphetamine, 
heroin, or something else” the past 12 months (no/yes).  
Mental distress. Mental distress was measured at T1 by 12 items from the Hopkins 
Symptom Checklist (46). The measure asks for ratings of symptoms of depression and anxiety 
the preceding week and applies a 4-point scale with the response options from 1 (not bothered 
at all) to 4 (extremely bothered). The items have been used in several studies to measure 
mental distress and have favorable psychometric properties (47). Mean scores were computed 
and internal consistency was high (Cronbach’s α = 0.85). 
 
Analyses 
Multinomial logistic regression analysis was conducted with prescription as dependent 
variable and cannabis use as the independent variable. The categories of “antipsychotics”, 
“mood-stabilizers”, “antidepressants”, “anxiolytics” and “psychotropic drugs on other 
indications” were all compared to the reference category “no psychotropic drugs”. We 
compared levels of cannabis exposure (“lifetime use but not last year” and “use last year”) 
with the reference category “no lifetime cannabis use”. We adjusted for potential confounders 
in four steps by including several indicators of socio-demographic background in a first step, 
adding variables related to conduct problems and drug use in a second step, and adding 
mental distress in a third step as covariates. Moreover, in a fourth step, we excluded all 
persons who had obtained prescriptions of psychotropic drugs in 2004 (n = 134), the year 
before information about cannabis exposure was obtained, to minimize the possibility of 
prescriptions of psychotropic drugs preceding cannabis use.  
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A maximum likelihood estimator was used in all analyses. Missing data were handled 
by means of full information maximum likelihood estimation, thereby providing missing data 
routines that are considered to be state of the art (48). The statistical program Mplus 7.4 was 
used for all regression analyses, and the commands “CATEGORICAL”, “ESTIMATOR = 
MLR” and “INTEGRATION = MONTECARLO” were used to specify the multinomial 





Of the total sample of 2,602 individuals, 317 (12.2%) reported use of cannabis during the past 
year, while 518 (19.9%) reported earlier use of cannabis but not the past year. During the 9 
year follow-up period, 33 individuals (1.3%) had received prescriptions for antipsychotics, 36 
individuals (1.4%) for mood-stabilizers, 233 individuals (9.0%) for antidepressants, 104 
individuals (4.0%) for anxiolytics and 82 persons (3.2%) had been prescribed psychotropic 
drugs for presumably other reasons than a mental disorder. The number of individuals who 
had not received any prescriptions for psychotropic drugs was 2,114 (81.4%). 
Those who were not prescribed any psychotropic drugs during follow-up were in 
adolescence more often living with their parents, had parents with higher education, had less 
conduct problems, smoked less and had less mental distress, compared to those with some 
type of prescription (Table 1). There were however considerable differences in how the 
background variables were distributed between the different psychotropic drug categories. 
There were differences between the cannabis categories on all variables except being born in 
Norway and use of other illicit drugs (Table 2).  
 
Insert Tables 1 and 2 here 
 
The unadjusted results of the multinomial regression analyses showed a strong 
association with later prescription of antipsychotics and mood-stabilizers in those reporting 
last year cannabis use, and a significant but smaller association to prescription of 
antidepressants and anxiolytics (Table 3). This pattern remained through the four steps of 
adjustment, with the final model estimating past year cannabis use to be associated with an 
increased odds ratio for filling a prescription of antipsychotics of OR = 5.56 (1.64 – 18.87), 
prescription of mood-stabilizers of OR = 5.36 (95 % CI 1.99 – 14.44) and prescription of 
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antidepressants of OR = 2.10 (1.36 – 3.25). The association to prescription of anxiolytics 
became non-significant after adjustments. Through the four steps of modelling the estimates 
of the associations were only slightly changed, and for some associations the effect size 
increased after adjustment.  
Lifetime cannabis use but no use during the past year, showed no significant 
associations with any prescription outcome in any model.  
 





In this longitudinal cohort study of a population-based sample of young adults, we found that 
past year cannabis use was associated with later prescription of antipsychotics, mood-
stabilizers and antidepressants. The associations remained significant and with almost 
unaltered effect-sizes after adjustment for relevant background variables including baseline 
mental distress and when excluding those with prescription for psychotropic drugs the year 
before the measurement of cannabis use. The association to anxiolytics was not significant 
after adjustment. 
The association between cannabis exposure and prescription of antipsychotics is in 
accordance with existing knowledge on the association between cannabis and psychosis. 
Several large, prospective, longitudinal epidemiologic and clinical studies have found that 
cannabis use, particularly heavy exposure that starts at an early age, increases the risk of 
developing schizophrenia (6-8, 11, 49, 50) and psychotic symptoms (9, 51, 52). To our 
knowledge, prescription data on antipsychotic medication has not been used as outcome in 
previous studies, and the present investigation thus supplements the evidence.  
 Our result of a robust association between cannabis use and prescription of mood 
stabilizers strengthens the relatively new assumption of cannabis use as a risk factor for 
bipolar disorder (29, 30). The effect size for the association between cannabis and mood 
stabilizers was comparable to the effect size for association between cannabis and 
antipsychotics, a magnitude similar also to the effect sizes found in studies using a diagnosis 
of bipolar disorder as outcome (26, 27, 53). It has been shown that cannabis use increases the 
risk for earlier onset bipolar disorder (19, 54), and the participants in this study were quite 
young adults. 
The smaller but significant association between cannabis use and antidepressants 
prescriptions found in this study is in accordance with most of the literature on cannabis and 
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depression (31-34). Further, the absence of an association between cannabis and anxiolytics in 
our study is informative for the understanding of the effect of cannabis use on anxiety, as 
meta-analysis provide conflicting results (34, 36). We have earlier commented that the use of 
benzodiazepines is greater in cannabis users (55), but the more careful grouping of 
psychotropic drug users in the present study indicates that this may be because 
benzodiazepines often are used also for other psychiatric illnesses than anxiety disorder. 
Only “past year use” significantly predicted prescriptions of the psychotropic drugs, 
while “lifetime use but not during the past year” seemed to infer no increased risk. This may 
reflect that the “past year use” category included those who continued their cannabis habits 
from youth into early adulthood, thus indicating longer exposure. Many studies demonstrate 
stronger association between frequent use and the outcome than for the association between 
any use and the same outcome (5, 31, 33), a dose-response pattern consistent with inferring 
causality. The “lifetime use but not during the past year” is a broad category, encompassing 
individuals who may have tried cannabis only a few times in their youth, or even just once.  
No particular variable or set of variables explained the association between cannabis 
use and later prescriptions in the sample. Adjusting for socio-demographic variables increased 
the effect size somewhat for all outcomes except antipsychotics. School truancy and conduct 
problems were associated with cannabis use, in line with previous research documenting 
cannabis use to be associated with school drop-out and poor educational attainments (56, 57). 
However, adjusting for school-variables, conduct problems and drug use imposed only a 
small decrease in the ORs. It should however be noted that drug use was measured at T1, 
leaving open the possibility that later drug use may have affected the outcome. Also, despite 
the significant differences in baseline mental distress between those with and without 
prescriptions, adjusting for baseline mental distress did not alter the effect sizes. Removing 
persons who had received prescriptions of psychotropic drugs the year prior to the self-
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reported cannabis use limits the risk of reversed causality. However, mental disorders may 
develop slowly, the prodromal phase of psychosis may for instance last years (58), and we 
cannot rule out that some have used cannabis to relieve early symptoms of mental illness.  
We do not know how well prescriptions function as a measure for a mental disorder. 
Most psychotropic drugs may have several uses. Before the rules of categorization were 
applied to the dataset, we reviewed each person’s total history of prescriptions to examine if 
the rules seemed reasonable. In spite of this effort to increase likelihood of correct 
approximation, it must be kept in mind that the psychotropic categories where only proxies 
for mental health diagnosis. Most significantly, antidepressants are also used for the treatment 
of anxiety and benzodiazepines are not recommended for long-term anxiety treatment, 
making the “antidepressants” and “anxiolytics” categories less valid as proxies for a mental 
disorder. Also, the proportion receiving treatment of those who have a mental disorder may 
not be equal across diagnostic categories, and the treatment-coverage is probably highest for 
psychotic disorders (59). It is however unlikely that this could explain the entire difference in 
associations between cannabis use and later  psychotic vs. non-psychotic prescriptions found 
in the present study. Lastly, we do not know if the prescribed drugs in fact were taken, but 
when using prescriptions as a proxy for disease, compliance is less of an issue.  
It would have been preferable with a more fine-graded differentiation of the cannabis 
exposure, enabling an investigation of potential dose-response relationships to the 
psychotropic drugs outcomes. The number of individuals in each group was however too 
small for such analysis to be conducted.  
Despite these limitations, an advantage of using this prescription database is that both 
patients from primary health care and the specialized health care are included. As Norway is a 
country with a comprehensive publicly financed health care system, access to mental health 
care (including prescriptions) should be based on illness severity, not on private economy 
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(60). Also, most limitations affect all the diagnostic categories equally and cannot explain the 
differences in results for the psychotropic drugs outcomes found in this study. 
This study is informative to the field as it has a relative large population-based sample, 
includes numerous relevant confounders, and expands the knowledge from previous studies 
by using prescription data as outcome. The results are indicative of a prospective association 
between cannabis use and psychosis, bipolar disorder and depression. This is important 




Table 1. Cannabis use, socio-demographics, conduct problems, drug use, and depression according to filling prescriptions for psychotropic drugs 
  No psychotropic 
drugs 





  n=2,114 (81.2%) n=33 (1.3%) n=36 (1.4%) n=233 (9.0%) n=104 (4.0%) n=82 (3.2%) p 
Cannabis use         
never used n (%) 1,428 (69.1%) 14 (45.2%) 15 (45.5%) 133 (58.6%) 62 (60.8%) 54 (66.7%)  
used before but not last year n (%) 419 (20.3%) 4 (12.9%) 7 (21.2%) 51 (22.5%) 23 (22.5%) 14 (17.3%)  
used last year n (%) 220 (10.6%) 13 (41.9%) 11 (33.3%) 43 (18.9%) 17 (16.7%) 13 (16.0%)  
Socio-demographics         
Female gender n (%) 1,137 (53.8%) 15 (45.5%) 25 (69.4%) 154 (66.1%) 71 (68.3%) 55 (67.1%) < 0.001 
Age mean (SD) 15.24 (1.87) 14.88 (3.18) 15.14 (3.04) 15.28 (2.15) 15.34 (1.92) 15.41 (2.42) 0.818 
Born in Norway n (%) 1,925 (97.0%) 27 (93.1%) 32 (94.1%) 214 (96.8%) 96 (97.0%) 75 (98.7%) 0.667 
Parental education mean (SD) 3.42 (1.12) 3.08 (1.13) 3.33 (1.18) 3.16 (1.07) 3.33 (1.13) 3.20 (1.08) 0.023 
Living with both parents n (%) 1,450 (71.5%) 20 (64.5%) 24 (70.6%) 130 (57.5%) 57 (55.3%) 55 (70.5%) < 0.001 
Conduct problems and drug use         
Conduct problems mean (SD) 1.34 (0.37) 1.36 (0.35) 1.37 (0.46) 1.41 (0.40) 1.44 (0.53) 1.42 (0.45) 0.022 
Alcohol intoxication mean (SD) 1.88 (1.42) 1.54 (1.10) 1.57 (1.25) 2.11 (1.46) 2.08 (1.60) 2.12 (1.48) 0.043 
Daily smoking n (%) 176 (9.1%) 3 (10.0%) 5 (14.7%) 37 (17.0%) 20 (20.2%) 7 (10.0%) < 0.001 
Other illicit drugs than cannabis n (%) 11 (0.6%) 0 (0.0%) 1 (3.3%) 5 (2.3%) 2 (2.0%) 0 (0.0%) 0.026 
Self-reported depression         





Table 2. Socio-demographics, conduct problems, drug use, and mental distress according to cannabis use 
  Never used cannabis Used cannabis before but 
not last year 
Used cannabis last year Difference test 
    n=1,706 (67.1%) n=518 (20.4%) n=317 (12.5%) p 
Socio-demographics      
Female gender n (%) 1,024 (60.0%) 271 (52.3%) 123 (38.8%) < 0.001 
Age mean (SD) 15.34 (1.98) 15.20 (1.89) 14.75 (1.84) < 0.001 
Born in Norway n (%) 1,559 (97.4%) 472 (96.7%) 286 (95.7%) 0.214 
Parental education  mean (SD) 3.32 (1.10) 3.51 (1.11) 3.55 (1.20) < 0.001 
Living with both parents n (%) 1,204 (73.8%) 318 (63.3%) 175 (56.6%) < 0.001 
Conduct problems and drug use      
Conduct problems mean (SD) 1.29 (0.32) 1.46 (0.45) 1.52 (0.49) < 0.001 
Alcohol intoxication mean (SD) 1.77 (1.33) 2.22 (1.59) 2.13 (1.54) < 0.001 
Daily smoking n (%) 126 (8.0%) 72 (15.3%) 47 (16.2%) < 0.001 
Other illicit drugs than cannabis n (%) 10 (0.6%) 6 (1.3%) 3 (1.0%) 0.375 
Self-reported depression      




Table 3. Results of logistic regression analyses with prescription of psychotropic drugs as outcome 
 Antipsychotics Mood stabilizers Antidepressants  Anxiolytics 
Other psychotropic 
drugs 
  OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Baseline Model: Unadjusted associations 
Cannabis use           
 never used  (reference) (reference) (reference) (reference) (reference) 
 used before but not last year 0.98 0.32-3.01 1.59 0.65-3.89 1.31 0.93-1.84 1.27 0.78-2.07 0.88 0.49-1.61 
 used last year 5.92*** 2.77-12.62 4.66*** 2.15-10.09 2.10*** 1.45-3.04 1.78* 1.02-3.10 1.56 0.84-2.92 
Model 1: Control for socio-demographics 
Cannabis use           
 never used  (reference) (reference) (reference) (reference) (reference) 
 used before but not last year 0.94 0.29-3.04 1.87 0.76-4.56 1.31 0.92-1.87 1.26 0.76-2.09 0.96 0.52-1.75 
 used last year 5.49*** 2.29-13.16 6.50*** 3.01-14.06 2.29*** 1.54-3.41 1.91* 1.06-3.43 1.92* 1.01-3.67 
Model 2: Additional adjustment for conduct problems and drug use† 
Cannabis use           
 never used  (reference) (reference) (reference) (reference) (reference) 
 used before but not last year 0.96 0.29-3.18 1.95 0.78-4.84 1.25 0.87-1.78 1.16 0.71-1.91 0.92 0.49-1.72 
 used last year 5.73*** 2.44-13.47 6.60*** 2.98-14.62 2.11*** 1.42-3.16 1.66 0.91-3.02 1.83 0.95-3.56 
Model 3: Additional adjustment for mental distress 
Cannabis use           
 never used  (reference) (reference) (reference) (reference) (reference) 
 used before but not last year 0.94 0.29-3.07 1.94 0.78-4.82 1.21 0.85-1.73 1.16 0.71-1.91 0.92 0.49-1.72 
 used last year 6.06*** 2.49-14.76 6.77* 3.05-14.99 2.18*** 1.45-3.26 1.66 0.91-3.25 1.83 0.94-3.55 
Model 4: Additional adjustment for use of psychotropic drugs in 2004‡ 
Cannabis use           
 never used  (reference) (reference) (reference) (reference) (reference) 
 used before but not last year 1.11 0.28-4.34 1.53 0.41-5.63 1.19 0.80-1.75 1.15 0.69-1.93 0.99 0.51-1.93 
 used last year 5.56** 1.64-18.87 5.36*** 1.99-14.44 2.10*** 1.36-3.25 1.61 0.84-3.07 1.80 0.87-3.70 
Note. OR = Odds ratio; 95% CI = 95% confidence interval of OR; *p < 0.05, **p < 0.01, **p < 0.001. 
†Illicit drug use was not included as covariate because the model did not converge due to low frequencies of such use in some of the drug prescription groups.  
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